|
|
Volumn 359, Issue 11, 2008, Pages 1092-1095
|
|
Assessing the cardiovascular safety of diabetes therapies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA GLUCOSIDASE INHIBITOR;
AMYLIN DERIVATIVE;
BILE ACID SEQUESTRANT;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
GLUCAGON LIKE PEPTIDE 1 DERIVATIVE;
INSULIN;
METFORMIN;
MURAGLITAZAR;
PHENFORMIN;
ROSIGLITAZONE;
SULFONYLUREA;
ANTIDIABETIC AGENT;
ABSENCE OF SIDE EFFECTS;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL ASSESSMENT;
CLINICAL TRIAL;
DIABETES CONTROL;
HUMAN;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SHORT SURVEY;
ADVISORY COMMITTEE;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
METHODOLOGY;
POSTMARKETING SURVEILLANCE;
RANDOMIZED CONTROLLED TRIAL;
STANDARD;
UNITED STATES;
ADVISORY COMMITTEES;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
DRUG APPROVAL;
HUMANS;
HYPOGLYCEMIC AGENTS;
PRODUCT SURVEILLANCE, POSTMARKETING;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 51649108902
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp0805758 Document Type: Article |
|
Times cited : (101)
|
|
References (5)
|
